恶性脑膜瘤进展过程中与良性脑膜瘤相比的基因表达分析
该研究采用NanoString靶向基因表达面板(聚焦787个脑膜瘤病理与神经炎症通路相关基因)分析2000至2020年在Rigshospitalet治疗的51例WHO III级脑膜瘤患者,并纳入其既往I、II级及III级复发样本共139个脑膜瘤。结果显示III级脑膜瘤中FOXM1、TOP2A、BIRC5、MYBL2富集且HOTAIR调控通路富集,小胶质细胞调控基因可区分良恶性,FOXM1在组织学转化前数年即已上调。
要点
- III级脑膜瘤中FOXM1、TOP2A、BIRC5、MYBL2富集,HOTAIR调控通路富集。
- 仅基于小胶质细胞调控基因即可区分良恶性脑膜瘤,P2RY12在I级较III级富集。
- FOXM1在III级转化前数年的癌前I级脑膜瘤中已上调。
核心结论
- 低级别脑膜瘤中已存在早于组织学转化为III级的基因表达改变。
- 神经炎症基因可区分III级与I级脑膜瘤。
研究设计与样本
- 采用NanoString靶向基因表达面板,聚焦787个脑膜瘤病理与神经炎症通路相关基因。
- 纳入2000至2020年在Rigshospitalet治疗的III级脑膜瘤患者51例,共139个脑膜瘤样本(含既往I、II级及III级复发样本)。
主要发现
- 与无复发I级脑膜瘤相比,III级脑膜瘤中FOXM1、TOP2A、BIRC5、MYBL2富集,HOTAIR调控通路富集。
- 仅基于小胶质细胞调控基因即可区分恶性与良性脑膜瘤,P2RY12在I级较III级富集。
- FOXM1在III级转化前数年的癌前I级脑膜瘤中已上调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Meningioma is the most common primary intracranial neoplasm. Only 1%-3% of meningiomas are malignant according to the 2016 WHO criteria (WHO grade III). High-grade meningiomas present specific gene expression signatures indicating aggressive growth or recurrence. However, changes in gene expression and in neuroinflammatory gene expression signatures in WHO grade III meningiomas and during progression from WHO grade I or II to grade III are unknown. METHODS: The authors used a NanoString targeted gene expression panel with focus on 787 genes relevant in meningioma pathology and neuroinflammatory pathways to investigate patients with grade III meningiomas treated at Rigshospitalet from 2000 to 2020 (n = 51). A temporal dimension was added to the investigation by including samples from patients' earlier grade I and II meningiomas and grade III recurrences (n = 139 meningiomas). The authors investigated changes in neuroinflammatory gene expression signatures in 1) grade I meningiomas that later transformed into grade III meningiomas, and 2) grade III meningiomas compared with nonrecurrent grade I meningiomas. RESULTS: The authors' data indicate that FOXM1, TOP2A, BIRC5, and MYBL2 were enriched and the HOTAIR regulatory pathway was enriched in grade III meningiomas compared with nonrecurrent grade I meningiomas. They discovered a separation of malignant and benign meningiomas based only on genes involved in microglia regulation with enrichment of P2RY12 in grade I compared with grade III meningiomas. Interestingly, FOXM1 was upregulated in premalignant grade I meningioma years before the grade III transformation. CONCLUSIONS: The authors found gene expression changes in low-grade meningiomas that predated histological transformation to grade III meningiomas. Neuroinflammation genes distinguished grade III from grade I meningiomas.
引用
- Maier AD, Meddis A, Mirian C, et al. Gene expression analysis during progression of malignant meningioma compared to benign meningioma. J Neurosurg. 2022. PMID: 36115056. doi:10.3171/2022.7.JNS22585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。